This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/pharmgkb/
n28http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/bindingdb/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/pubchem-compound/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/pubchem-substance/
n26http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n31http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n32http://linked.opendata.cz/resource/drugbank/drug/DB00238/identifier/chebi/
n30http://linked.opendata.cz/resource/atc/
n27http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00238
rdf:type
n4:Drug
n4:description
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem] Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
n4:dosage
n29:271B62DC-363D-11E5-9242-09173F13E4C5 n29:271B62DD-363D-11E5-9242-09173F13E4C5 n29:271B62DE-363D-11E5-9242-09173F13E4C5 n29:271B62DF-363D-11E5-9242-09173F13E4C5
n4:generalReferences
# FDA label
n4:group
approved
n4:halfLife
45 hours
n4:indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
n4:manufacturer
n14:271B62DA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00238 n26:DB00238
dcterms:title
Nevirapine
adms:identifier
n10:PA450616 n11:4463 n12:0597-0046-60 n13:NVP n15:C07263 n16:D00435 n17:DB00238 n18:1434 n19:4308 n20:46506789 n32:63613 n33:Nevirapine
n4:mechanismOfAction
Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
n4:packager
n14:271B62D9-363D-11E5-9242-09173F13E4C5 n14:271B62D7-363D-11E5-9242-09173F13E4C5 n14:271B62D8-363D-11E5-9242-09173F13E4C5 n14:271B62D1-363D-11E5-9242-09173F13E4C5 n14:271B62D2-363D-11E5-9242-09173F13E4C5 n14:271B62D5-363D-11E5-9242-09173F13E4C5 n14:271B62D6-363D-11E5-9242-09173F13E4C5 n14:271B62D3-363D-11E5-9242-09173F13E4C5 n14:271B62D4-363D-11E5-9242-09173F13E4C5
n4:patent
n23:5366972 n23:2030056
n4:routeOfElimination
Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
n4:synonym
Nevirapine NEV 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one NVP Viramune
n4:toxicity
Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease. The most common adverse reaction is rash.
n4:volumeOfDistribution
* 1.21 ± 0.09 L/kg [apparent volume of distribution, healthy adults, IV] Nevirapine is capable of crossing the placenta and is found in breast milk.
n27:hasAHFSCode
n28:08-18-08-16
n4:foodInteraction
Take without regard to meals. Avoid alcohol.
n4:proteinBinding
60% bound to plasma protein.
n4:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Nevirapine.htm
n7:hasConcept
n8:M0029429
foaf:page
n22:nevirapine.html n31:nevira.htm
n4:IUPAC-Name
n5:271B62E4-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B62EA-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B62E9-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B62E6-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B62E7-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B62E8-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B62E2-363D-11E5-9242-09173F13E4C5 n5:271B62FA-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B62E0-363D-11E5-9242-09173F13E4C5 n5:271B62E3-363D-11E5-9242-09173F13E4C5 n5:271B62FC-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B62E1-363D-11E5-9242-09173F13E4C5
n27:hasATCCode
n30:J05AG01
n4:H-Bond-Acceptor-Count
n5:271B62F0-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B62F1-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B62EB-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B62EC-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B62EE-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B62ED-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B62EF-363D-11E5-9242-09173F13E4C5
n4:absorption
Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state.
n4:affectedOrganism
Human Immunodeficiency Virus
n4:caco2-Permeability
n5:271B62FD-363D-11E5-9242-09173F13E4C5
n4:casRegistryNumber
129618-40-2
n4:category
n4:containedIn
n6:271B62DB-363D-11E5-9242-09173F13E4C5
n4:Bioavailability
n5:271B62F6-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B62F8-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B62F9-363D-11E5-9242-09173F13E4C5
n4:Melting-Point
n5:271B62FB-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B62F5-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B62F4-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B62F7-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B62E5-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B62F2-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B62F3-363D-11E5-9242-09173F13E4C5